Suppr超能文献

肥胖相关性高血压中的微血管功能障碍

Microvascular Dysfunction in Obesity-Hypertension.

机构信息

Department of Medicine, LSU Health Sciences Center - New Orleans, New Orleans, LA, USA.

Section of Nephrology and Hypertension, LSU Health Sciences Center - New Orleans, 2021 Perdido Street, Ste 4325, New Orleans, LA, 70112, USA.

出版信息

Curr Hypertens Rep. 2023 Dec;25(12):447-453. doi: 10.1007/s11906-023-01272-2. Epub 2023 Oct 14.

Abstract

PURPOSE OF REVIEW

This review aims to explore the role of microvascular dysfunction in obesity-hypertension, discuss the effects obesity has on renal microvasculature, review the current methods for assessing microvascular dysfunction and available therapeutic options, and identify critical areas for further research.

RECENT FINDINGS

There is a strong association between obesity and hypertension. However, the pathophysiology of obesity-hypertension is not clear. Microvascular dysfunction has been linked to hypertension and obesity and could be an important mediator of obesity-related hypertension. Newer therapies for hypertension and obesity could have ameliorating effects on microvascular dysfunction, including GLP-1 agonists and SGLT-2 inhibitors. There is still much progress to be made in our understanding of the complex interplay between obesity, hypertension, and microvascular dysfunction. Continued efforts to understand microvascular dysfunction and its role in obesity-hypertension are crucial to develop precision therapy to target obesity-hypertension.

摘要

目的综述

本综述旨在探讨微血管功能障碍在肥胖相关性高血压中的作用,讨论肥胖对肾脏微血管的影响,综述评估微血管功能障碍的当前方法和可用的治疗选择,并确定进一步研究的关键领域。

最近的发现

肥胖与高血压之间存在密切关联。然而,肥胖相关性高血压的病理生理学机制尚不清楚。微血管功能障碍与高血压和肥胖有关,可能是肥胖相关性高血压的重要介导因素。高血压和肥胖的新疗法可能对微血管功能障碍有改善作用,包括 GLP-1 激动剂和 SGLT-2 抑制剂。我们对肥胖、高血压和微血管功能障碍之间复杂相互作用的理解仍有很大的进展空间。为了开发针对肥胖相关性高血压的精准治疗方法,继续努力理解微血管功能障碍及其在肥胖相关性高血压中的作用至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验